Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- Private equity owns less than 4% of U.S. hospitals, study finds (Medical Xpress)
- FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help? (HCP Live)
- Greg O’Grady: The Surgeon Who Left Surgery to Map the Stomach (Gut Health Times)
- GI Practices Lose More on Second Procedures Than Any Other Specialty, Jiro Health Benchmark Finds (PR Newswire)
- Throne Announces First Clinical Validation Study, Demonstrating Its AI-Powered Stool Classification Performs Comparably to Board-Certified Gastroenterologists (Business Wire)
- Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows (Clinical Lab Products)
- For Better or Worse, Monitored Anesthesia Care Is Now the Default in GI Endoscopy (GI & Endoscopy News)
- AI ‘may offer an efficient way’ to detect colorectal neoplasia, but more research needed (Healio)
